VG—003

Lorem ipsum dolor sit amet consectetur. Viverra tellus quisque congue habitant non odio eget mattis posuere. Adipiscing ac netus odio hac. Pellentesque iaculis nunc vitae purus. Orci malesuada urna vitae nisl in at diam. Tortor amet nunc in elementum sodales ultricies placerat eget sem. Consequat cras arcu proin venenatis pellentesque eu mattis amet. Ipsum magna ut mi fermentum commodo in adipiscing. Velit purus velit lobortis neque libero. Suspendisse enim sit eros in adipiscing. Ultricies gravida non dui cras aliquet. Venenatis ac est tristique sollicitudin. Euismod viverra lectus laoreet id non id aliquam. Turpis dolor cursus sed curabitur. Pulvinar vel gravida et mus. Nunc nec risus enim viverra ac risus sit metus nullam tincidunt.
Astronauts
#0011
United States
#0014
Antigua & Barbuda
#0014
Antigua & Barbuda
#0014
Italy
Crew
Jameel Janjua
Italy
Nicola Pecile
Antigua & Barbuda
Tuva Cihangir Atasever
Turkey
Andrew Dutton
United States
Take-Off Time
8:31 MT
Altitude at Release
44,562 FT
Apogee
54.4 MI
Top Speed
2.96 MACH
Landing Time
9:41 MT
Axiom Space and TUA – Suborbital Testing of Insulin Pens
This experiment serves as a stepping stone to support astronauts with insulin-dependent diabetes and demonstrates a capability necessary for maintenance therapy and hyperglycemic states in insulindependent people with diabetes. This human-tended experiment includes two commercially available insulin pens, which will each be secured in a custom 3D-printed container during flight. During the flight, Tuva will retain the insulin pens in his flight suit, dial an insulin dose, and dispense insulin from each pen into a collection container to study the accuracy of dose dispensation in microgravity. Commercial spaceflight and the research flown on these missions are opening space to people with diabetes and those who previously have not been eligible to fly to space.
Principal Investigator
Dr. John Marshall and Mr. Alex Rubin
Researcher
Tuva Atasever, Astronaut 027
Flight
Galactic 07
Date
2024
Contractor
Axiom Space